Comments on FDA’s PMA eSTAR Draft Guidance
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest and never sell or share it. See our privacy policy.
Explore the engineering, technology and compliance shifts shaping medtech in 2026, from patient-centric innovation to evolving global frameworks.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story.
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | +0.52% | -0.04% | base | -1.40% | after close | after close | after close |
| XBI | +6.26% | +3.61% | base | -0.42% | after close | after close | after close |
| LLY | -0.12% | -0.28% | base | -1.28% | after close | after close | after close |
| JNJ | -0.65% | +0.33% | base | -1.38% | after close | after close | after close |
| PFE | +1.66% | -0.17% | base | -1.45% | after close | after close | after close |
| MRK | +2.39% | +1.67% | base | -0.80% | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Comments on FDA’s PMA eSTAR Draft Guidance AdvaMed® - Advanced Medical Technology Association®
Select Sector Spdr Tr (XLV)
Those 4 earlier stories put Select Sector Spdr Tr (XLV) at an average move of -1.92% the next day. Largest gain -1.92%, largest drop -1.92%, from 4 prices.
| Company | When | Average | Largest gain | Largest drop | Prices |
|---|---|---|---|---|---|
| Select Sector Spdr Tr (XLV) | the next day | -1.92% | -1.92% | -1.92% | 4 |
| Spdr Series Trust (XBI) | the next day | -3.49% | -3.49% | -3.49% | 2 |
| Eli Lilly (LLY) | the next day | -2.01% | -2.01% | -2.01% | 3 |
| Johnson & Johnson (JNJ) | the next day | -2.54% | -2.54% | -2.54% | 3 |
- Fundació Puigvert warns that cybersecurity across the entire healthcare ecosystem is key to protecting patients
- Medicaid Work Requirement Delay Pushes Molina, Centene Stocks Higher
- Summit shares fall as FDA rejects closely watched PD-1/VEGF drug
- 12 Health Care Stocks Moving In Monday's Intraday Session
The price since 17 Nov 2026: Select Sector Spdr Tr (XLV) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| Johnson & Johnson (JNJ) | that day | -1.38% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +0.33% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -0.65% | final price |
| Eli Lilly (LLY) | that day | -1.28% | final price |
| Eli Lilly (LLY) | three days earlier | -0.28% | final price |
| Eli Lilly (LLY) | five days earlier | -0.12% | final price |
| Merck (MRK) | that day | -0.80% | final price |
| Merck (MRK) | three days earlier | +1.67% | final price |
| Merck (MRK) | five days earlier | +2.39% | final price |
| Pfizer (PFE) | that day | -1.45% | final price |
| Pfizer (PFE) | three days earlier | -0.17% | final price |
| Pfizer (PFE) | five days earlier | +1.66% | final price |
| Spdr Series Trust (XBI) | that day | -0.42% | final price |
| Spdr Series Trust (XBI) | three days earlier | +3.61% | final price |
| Spdr Series Trust (XBI) | five days earlier | +6.26% | final price |
| Select Sector Spdr Tr (XLV) | that day | -1.40% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.04% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | +0.52% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 14 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 28 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 74 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 41 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 48 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 53 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 74 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 88 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 90 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “Comments on FDA’s PMA eSTAR Draft Guidance”
Companies carried with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 17 Nov 2026 story “Comments on FDA’s PMA eSTAR Draft Guidance.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- XBI Spdr Series Trust
For “Comments on FDA’s PMA eSTAR Draft Guidance,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
- LLY Eli Lilly
In “Comments on FDA’s PMA eSTAR Draft Guidance,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- JNJ Johnson & Johnson
In “Comments on FDA’s PMA eSTAR Draft Guidance,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- PFE Pfizer
In “Comments on FDA’s PMA eSTAR Draft Guidance,” Pfizer (PFE) is linked, with no stored direction, medium confidence. Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
- MRK Merck
Merck (MRK) is linked, with no stored direction, medium confidence in the 17 Nov 2026 story “Comments on FDA’s PMA eSTAR Draft Guidance.” Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “fda” (pharma and health) in this story
How “Comments on FDA’s PMA eSTAR Draft Guidance” reaches Select Sector Spdr Tr (XLV)
Select Sector Spdr Tr (XLV) is the company in “Comments on FDA’s PMA eSTAR Draft Guidance,” the 17 Nov 2026 this story story.
What ties Select Sector Spdr Tr (XLV) to the headline is this: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
Also listed, Spdr Series Trust (XBI): SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “fda” (pharma and health) in this story
Dates and price levels for Select Sector Spdr Tr (XLV)
LLY traded between 1239.21 and 1458.90 across 20 sessions. The latest close on file is 1430.09.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“Comments on FDA’s PMA eSTAR Draft Guidance” scores 46 out of 100. The score uses 1 source, and 6 linked companies.